Marc completed his studies in Biology at the University of Freiburg (Germany) and the University of Queensland (Australia). He holds a PhD in Biotechnology from the ETH Zurich. Besides his excellent skills in molecular biology, he gained business experience as Associate Intern at McKinsey & Company and insights to intellectual property rights at the patent offices Ernest T. Freylinger SA (Luxemburg) and Joachim Stuercken GmbH (Germany). Marc is winner of the Venture Leaders 2008 award.
PhD in Neuropharmacology (University Paris Descartes) and titular of a Master’s degree in Company Management (CNAM-International Institut of Management), Antony Lebeau has successively worked as research engineer (Inserm/Research Institut of Servier), project manager (GIS Prion-Ministry of Research, Inserm Transfert), communication manager (Inserm-Tranfert and Inserm-Transfert Initiative. He joined the French National Research Agency (ANR) as project manager in the of « Health Biology » department, working on Technology Transfer programs (RIB/Biotecs ,TecSan). He currently works as program officer in the ANR department of « Investments for the future and competitiveness », working in the field of public-private partnerships. Antony Lebeau has been also expert for the European Commission and for the ERC in « Health and Biotechnology » and « Ethic and Governance » fields for the past 8 years.
Dr. Pierre Legrain, PhD in Genetics, has published over 80 scientific articles and has a solid research and management background. Recently he had the responsibility of Master and PhD students at the Graduate School of Ecole Polytechnique. Until 2012, he coordinated the evaluation of public research in the life sciences at AERES. He joined the CEA (French Alternative Energies and Atomic Energy Commission) in 2003 at the Direction of Biology Department of Joliot-Curie, and later on managed the CEA Life Sciences Division. Pierre started as Laboratory Director at Institut Pasteur in 1995, where he created and managed the first start-up: Hybrigenics.
Dr Legrain’s key role at the Development Department at the Institut Pasteur is to foster the development of transversal research programs, some of which concern major human health areas, such as vaccinology, microbiology, oncology and brain science. These programs involve both Institut Pasteur Campus teams and the entire Institut Pasteur international network. In the initial stages, these programs were self-financed but they now attract new partners, from the industry and from foundations and funding agencies, in France and abroad.
Rafi Mardachti is a Pharmacist (Pharm.D) from the University of Paris XI (France). He has an MBA from the Albany College of Pharmacy of Union University (USA). He is a Master of Pharmaceutical Marketing from the University of Paris XI (France). He is the winner of the National Thesis prize in 1995: Mail Order Pharmacy.
His previous positions were: Regional District Manager at MEDCO (USA), Pharmacist Manager at Marionnaud (France), Health Manager Director at Quintiles (Europe). He is the founder and CEO of Universal Medica.
Rafi Mardachti has published various articles in specialized media and teaches at various schools and specialized Master’s degrees.
Mallory Perrin-Wolff has joined the Institut Pasteur in Paris late 2014 as the head of the Incentive Research Programs and Partnerships Department, part of the Development Department. Her current goals and challenges are (1) to source, launch and support a series of strategic research programs by using Institut Pasteur seed funding for the early-stage and (2) to seek partnerships for further development and funding for those programs.
She was previously Director of Strategic Partnerships & Alliances at Inserm Transfert with a specific goal on Open innovation area. She has a 15-year experience in the Technology Transfer covering biomedical research and human health. She joined Inserm Transfert in 2006 where she progressively became a Business Development/Licensing executive, in charge of the Immunology-inflammation domain with a strong focus on biopharmaceuticals (therapeutic monoclonal antibodies and technology platforms). She has a broad experience of public-private partnership between the academic research and worldwide Biotech/biopharma Industry developing Open innovation deals, early-stage in-licensing, technical evaluation and alliance management.
Mallory holds a Ph.D in Immunology and Molecular pharmacology (University Paris Descartes, France) with extensive experience in oncology and endocrinology area (post-doctoral and Inserm scientific positions).
Convaincue que le développement économique et sociétal passe par l’innovation, Chantal Vernis s’engage depuis plus de 15 ans à impulser une nouvelle dynamique dans le transfert de connaissances, compétences et résultats de la recherche publique vers les entreprises.
Après avoir travaillé près de 20 ans dans l’industrie aérospatiale, elle a rejoint le CNRS où son investissement au sein de la Direction de l’Innovation et des Relations avec les Entreprises (DIRE) a conduit à la création de 300 entreprises innovantes à même d’exploiter les technologies mises au point dans des laboratoires de recherche.
Dans l’équipe de direction de la SATT Lutech dès sa création en 2012, elle œuvre à la mise en place de sa stratégie opérationnelle ainsi qu’à la structuration et à l’essor son activité. Depuis 2014, elle en assure également la présidence et déploie une politique audacieuse en cohérence avec celle des établissements de recherche et d’enseignement supérieur actionnaires de la société.
Nader Yaghoubi, M.D., Ph.D., is President and CEO of PathMaker Neurosystems, a clinical-stage neuromodulation company with operations in France and US. He has over 16 years of experience in the creation, operations and financing of life science companies. Prior to starting PathMaker, he was President and CEO of Symbiotix Biotherapies, a pioneering microbiome company emerging from Harvard Medical School. Before these, he was the first employee at Selecta Biosciences (Nasdaq:SELB) and BIND Therapeutics (Nasdaq:BIND), nanoparticle companies emerging from MIT. Previously, he was at Zero Stage Capital, a venture capital firm where he was responsible for investing in the life sciences sector, and was also an intern at Advent International. Dr. Yaghoubi received an M.D. and Ph.D. in Molecular Pharmacology from the combined degree program at Boston University School of Medicine. His doctorate work on the development of high-throughput automated electrophysiological systems resulted in five issued US patents, received one of his University’s highest awards for dissertational research, and was the basis of a venture-backed neuroscience company. He is extensively involved in mentoring young companies, and has served/serves as a mentor, advisor and reviewer with Massachusett’s Biotechnology Council’s MassCONNECT program, Mass Life Sciences Center programs, Springboard Venture Capital Forum and numerous university business plan competitions.